Table 2.
Proportion of Positive or Reactive Test Result from Pre-Seroconversion Plasma Specimens.
| Number (%) of Positive or Reactive Test Results | ||||
|---|---|---|---|---|
| Number of days that sample was collected prior to positive third generation rapid test result at the clinical site | 12–29 days | 30–59 days | 60–91 days | TOTAL |
| N=48 | N=98 | N=84 | N = 230 | |
| Roche TaqMan, v2.0 HIV-1 RNA ≥20 copies/mL or < 20 copies/mL, detected | 32 (67%) | 33 (34%) | 7 (8%) | 72 (31%) |
| Uni-Gold™ Recombigen® | 8 (17%) | 5 (5%) | 1 (1%) | 14 (6%) |
| OraQuick ADVANCE® | 6 (13%) | 1 (1%) | 2 (2%) | 9 (4%) |
| N=48 | N=98 | N=83a | N = 229a | |
| CE-Marked Alere™ HIV Combo | 16 (33%) | 14 (14%) | 2 (2%) | 32 (14%) |
| FDA-Approved Determine™ Combo | 12 (25%) | 6 (6%) | 1 (1%) | 19 (8%) |
| GS HIV-1/2 + O EIA | 13 (27%) | 8 (8%) | 2 (2%) | 23 (10%) |
| GS HIV Combo Ag/Ab EIA | 23 (48%) | 16 (16%) | 3 (4%) | 42 (18%) |
| Multispot HIV-1/HIV-2 | 7 (15%) | 4 (4%) | 1 (1%) | 12 (5%) |
| GS HIV-1 Western Blot | 6 (13%) | 3 (3%) | 1 (1%) | 10 (4%) |
| Geenius HIV-1/2 Supplemental | 6 (13%) | 4 (4%) | 1 (1%) | 11 (5%) |
a
One specimen was only tested by Roche TaqMan, Uni-Gold™ Recombigen® and OraQuick ADVANCE®.